RARA CRAFT DATABASE for FDA Medical Devices
PMAP220016

FDA DEVICE FACTS

HepQuant SHUNT® Liver Diagnostic Test

Hepquant, LLC

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJune 18, 2026PRODUCT CODESIO

Indications for use

The HepQuant SHUNT® Liver Diagnostic Test is designed for the quantitative detection of 13C-cholate and d4-cholate in human serum from blood samples collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The assay generates a Disease Severity Index (DSI) score from the clearance of 13C-cholate and d4-cholate. Sample analysis is conducted by the HepQuant Analytical Test Laboratory.

A DSI score below the validated threshold can be used in patients with compensated cirrhosis (Child Pugh Class A), age 22 years or older, undergoing screening or surveillance for esophageal varices to identify those patients unlikely to have large esophageal varices. The DSI score aids in identifying patients unlikely to require esophagogastroduodenoscopy (EGD) at the time of testing.

The HepQuant SHUNT® Liver Diagnostic Test is not a stand-alone test and should be used in conjunction with other clinical and laboratory findings.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: July 28, 2026